Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Chung Yuen Huen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Beta
- 0.17
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -5.85
Financials
Revenue
$0.00-100.0%Net Income
$-307.5KEBITDA
$-825.1KFree Cash Flow
$-535.3KEPS (diluted)
$-4.20Shares Outstanding (diluted)
73.5K+153.4%Operating Expenses
$708.9KCash & Debt
$3.45MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-1.36M | $-19.00 |
| 2024 | $0.00 | $-4.27M | $-78.00 |
| 2023 | $431.4K | $-2.83M | $-62.00 |
| 2022 | $1.30M | $-9.80M | $-275.00 |
| 2021 | $1.54M | $-25.05M | $-715.00 |
| 2020 | $911.5K | $7.07M | $203.00 |
| 2019 | $535.2K | $-18.69M | $-640.00 |
| 2018 | $383.4K | $-14.83M | $-531.00 |
| 2017 | $0.00 | $-2.55M | $-85.00 |
Valuation
NIKIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·5h ago·Neutral
Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine NYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research use
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
…o a multi-site Alzheimer's clinical research network PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs through advanced genomic and biomarker testing, today announced that DiamiR Biosciences, its wholly owned subsidiary, has signed an agreement to perform apolipoprotein E (APOE) genotyping for Charter Research, a multi-site clinical research organization that co…
View source ↗ - Newsglobenewswire.com·10d ago·Negative
Niki BioSolutions' Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation's “Rett Research Tool Belt” Series Company's blood-based microRNA biomarker panel is designed to support monitoring of disease progression and treatment response in Rett syndrome
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform
View source ↗
Earnings
Typical surprise -308.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Apr 30$51.00 vs $-27.00beat
- Fri, Dec 22$-14.30 vs $-26.00beat
- Fri, Apr 28$-2.22 vs $-0.26miss
- Fri, Apr 29$-2.52 vs $-0.33miss
Estimates and results for NIKI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NIKI officers and directors.
No open-market trades in the recent filings. All 8 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
8 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NIKI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.